A multicenter open-label non-inferiority randomized clinical trial comparing the safety (non-inferiority) of short antibiotic treatment (72 hours) with an anti-pseudomonal carbapenem with regard to treatment failure in comparison with extended treatment (at least 9 days) of high-risk febrile neutropenia in hematology patients receiving standard antimicrobial prophylaxis.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
The percentage of patients with failed treatment
Timeframe: Between randomization (at 3x24 hours) and before 9x24hours after treatment initiation)
Death/ARDS or Septic shock
Timeframe: From randomization until the end of neutropenia (neutrophil count >=0.5x10e9/L) up to 6 months after randomization.